Literature DB >> 9111546

Effects of riluzole on symptom progression in amyotrophic lateral sclerosis.

P Sojka, P M Andersen, L Forsgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9111546     DOI： 10.1016/s0140-6736(05)60977-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

2.  Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.

Authors:  A Messori; S Trippoli; P Becagli; G Zaccara
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 3.  [Genetics of amyotrophic lateral sclerosis].

Authors:  A Hübers; J H Weishaupt; A C Ludolph
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 4.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  Robert G Miller; J D Mitchell; Dan H Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

5.  Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism.

Authors:  Laura Ferraiuolo; Kathrin Meyer; Thomas W Sherwood; Jonathan Vick; Shibi Likhite; Ashley Frakes; Carlos J Miranda; Lyndsey Braun; Paul R Heath; Ricardo Pineda; Christine E Beattie; Pamela J Shaw; Candice C Askwith; Dana McTigue; Brian K Kaspar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-29       Impact factor: 11.205
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.